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ABSTRACT 
Neurofibromatosis 1 (NF1) is a genetic disease characterized by cutaneous, neurological 
and osseous complications. Although clinical manifestations of NF1 are variable, there 
has been no report on evaluation of severity in patients with NF1. To elucidate the grade 
of severity of NF1, a retrospective study was conducted in 124 NF1 patients at the 
Department of Dermatology of Tottori University Hospital in 2007-2016. The DNB 
classification (dermatological, neurological and bone manifestations) in Japan was used 
for assessment. 
Based on our current epidemiological data, there were 55 patients (44.3%) in stage 1, 23 
patients (18.6%) in stage 2, 3 patients (2.4%) in stage 3, 1 patient (0.8%) in stage 4 and 
42 patients (33.9%) in stage 5. The grade of severity in patients with NF1 tended to be 
higher with aging. Remarkably, 61.8% of the patients in stage 5 had diffuse plexiform 
neurofibromas with functional disability. We should pay attention to diffuse plexiform 
neurofibromas that greatly affect quality of life in patients with NF1. 
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Neurofibromatosis 1 (NF1, von Recklinghausen disease) is one of the most common 
autosomal dominant genetic diseases and is characterized by café-au-lait spots, 
neurofibromas, freckling, optic glioma, Lisch nodules and bone deformity.1, 2, 3 It is 
caused by mutation of the NF1 gene on chromosome 17q11.2.4 The worldwide 
prevalence of NF1 is approximately 1 in 3000-4000 individuals with nearly 100% 
penetrance.5, 6 
Clinical manifestations of NF1 are variable, and the overall degree of complications is 
not predictable. As far as we know, however, there is no report on evaluation of the 
severity index of each symptom in patients with NF1. Therefore, current 
epidemiological data are necessary. In Japan, the grade of severity is divided into 5 
stages based on the DNB classification (dermatological (D1-D4), neurological (N0-N2) 
and bone manifestations (B0-B2)).7    
In this study, we evaluated the recent prevalence of each manifestation in Japanese 
patients with NF1 to reveal the grade of severity of NF1 by DNB classification. 
 
PATIENTS AND METHODS 
Study population (Patients) 
A retrospective study was conducted. We investigated 124 NF1 patients (58 men and 66 
women; median age, 31 years; age range, 0-95 years) at the Dermatology Department of 
Tottori University Hospital over a 9-year period from January 2007 to October 2016.  
All of the patients were examined by expert dermatologists, and all met the diagnosis 
criteria by National Institutes of Health in 1988.6, 7 The study protocol was approved by 
the Ethics Committee of Tottori University Hospital (No. 2671).  
Demographic and clinical information including information on age, sex and any 
diagnosed complications was obtained from medical records. We estimated the grade of 
severity in each patient according to the DNB classification proposed by the Ministry of 




Café-au-lait spots are flat, well-circumscribed, light to dark macules that can be present 
at birth and become conspicuous as the infant grows. 2, 3. 
Neurofibromas can be classified into 3 types (cutaneous, nodular plexiform and diffuse 
plexiform neurofibromas). Cutaneous neurofibromas are dome-shaped, soft, 
flesh-colored nodules of 1 to 2 cm in size. They are detectable in most patients at 
puberty and increase in size and number with age. 8, 9 Plexiform neurofibroma is thought 
to be a congenital tumor that often causes disfigurement. 2, 3    
Cutaneous neurofibroma is always benign, whereas plexiform neurofibroma has a 
potential for malignant transformation into malignant peripheral nerve sheath tumor. 2, 3 
 
Neurological manifestations 
Optic pathway glioma is found in 15-20% of children with NF1. Up to half of these 
patients will develop visual symptoms.10  It has been reported to be rare among Asian 
populations.9 Cerebral glioma also occurs in up to 3% of patients. 
 
Bone manifestations  
Osseous abnormalities associated with NF1 include scoliosis, sphenoid wing dysplasia 
and long-bone dysplasia. Scoliosis affects 10-26% of patients with NF1.11 Sphenoid 
wing dysplasia is rarely seen (<1% of patients with NF1)12 and sometimes causes a 
pulsating exophthalmos or brain herniation.13 Long-bone dysplasia is rarely seen in 
infancy (approximately 2%) and can result in pseudoarthrosis.14 
 
Mosaic NF1 
Mosaic NF1 is caused by a somatic mosaicism of the NF1 mutation and shows typical 
features of NF1 limited to specific body segments. It has been reported that the 
prevalence of mosaic NF1 in the general population is 1 in 36,000-40,000 individuals.  
15, 16, 17 
 
Genetic analysis 
After obtaining informed consent, we performed genetic analysis of 25 NF1 patients by 
next-generation sequencing as previously described.18 Briefly, genomic DNA was 
extracted from peripheral blood according to standard procedures. In-solution 
hybridization-based enrichment was performed using the SureSelect Target Enrichment 
system (Agilent Technologies, Santa Clara, CA, USA). When the next-generation 
sequencing protocol revealed truncating mutations, the variants were validated by direct 
capillary sequencing. Exon deletions were screened using a multiple ligation-dependent 





There were 124 NF1 patients in this study (58 men and 66 women; median age, 31 
years). The numbers of patients were large in the under 10 years old group and 30-39 




The patients were divided into 4 groups according to the number of cutaneous 
neurofibromas (Fig. 2). The ratios of patients with <10 cutaneous neurofibromas, <100 
neurofibromas, <1000 neurofibromas and ≧1000 neurofibromas were 40.3%, 26.6%, 
25.8% and 7.3% respectively (Fig. 2).  A large number of cutaneous neurofibromas 
was seen in elderly patients. Cutaneous neurofibromas tended to increase with aging 
(Fig. 3).  
Nodular plexiform neurofibromas were seen in 14 patients (11.3%). Diffuse plexiform 
neurofibromas were observed in 26 patients (21%). Malignant peripheral nerve sheath 
tumor was found in only one patient (0.8%). These results are shown in TableⅡ.  
 
Neurological manifestations 
Optic pathway glioma was seen in 2 patients (1.6%) and cerebral glioma in 3 patients 
(2.4%) (TableⅡ).  
 
Bone manifestations 
Osseous abnormalities were seen in 16 patients (12.9%). There were 10 patients with 
spine deformity (9 patients with scoliosis and 1 patient with atlantoaxial subluxation), 5 
patients with deformity of the skull or facial bone and 1 patient with pseudoarthrosis 
(TableⅡ).  
 
Grade of severity in patients with NF1 based on DNB classification 
Based on the Japanese criteria, the patients were divided into 5 stages (TableⅠ). There 
were 55 patients (44.3%) in stage 1, 23 patients (18.6%) in stage 2, 3 patients (2.4%) in 
stage 3, 1 patient (0.8%) in stage 4 and 42 patients (33.9%) in stage 5 (Fig. 4a). 
Twenty-six (61.8%) of the patients in stage 5 had diffuse plexiform neurofibromas with 
functional disability (Fig. 4b). 
The stage of each patient is shown in Fig. 4c. In the 0-9 years old group, most patients 
were classified into a lower grade. The grade of severity in patients with NF1 tended to 
be higher with aging. 
 
Mosaic NF1 
In our study, there are 17 patients (13.7%) with mosaic NF1(9 men and 8 women; 
median age, 9 years; age range, 2-88 years) (not shown). 
 
Relationship between type of NF1 mutation and clinical severity  
NF1 mutation was detected 19 of the 25 patients (9 frameshift, 6 missense, 3 deletion 
and 1 nonsense). There was no significant relationship between type of NF1 mutation 
and clinical severity (not shown). 
 
DISCUSSION 
It is well known that NF1 has various complications including dermatological, 
neurological and bone manifestations.1, 2, 3 Although there has been a few reports on the 
frequency of complications in NF1,3, 9 the grade of severity has not been elucidated. 
Therefore, we investigated the grade of severity in Japanese patients with NF1 by 
epidemiological data in our institution. This is the first report on clinical severity of NF1 
patients by Japanese DNB classification. 
In our study, there were diphasic peaks (< 10 years old group and 30-39 years old 
group) in the number of NF1 patients. It is likely that the younger patients were referred 
to our hospital by pediatricians for evaluation of café-au-lait spots. In most patients <10 
years old, the grade of severity was low. In contrast, NF1 patients >30 years old 
presented with cosmetic and social problems due to dermatological manifestations 
(neurofibromas). We are not sure about the precise reason why the number of patients 
with age 30-39 is large and that of age 20-29 is small. The patients with age 20-29 may 
not have enough time to visit hospitals because they are busy for school or business. Or 
the number of cutaneous neurofibromas is relatively small in those patients, which does 
not affect daily life and social activity. 
We investigated the approximate number of cutaneous neurofibromas. The number of 
cutaneous neurofibromas tended to increase with advance of age. The ratio of patients 
with numerous neurofibromas (>1000 number) was not high (7.3%) in our study. This 
might be because elderly patients with severe dermatological manifestations hesitated to 
visit hospitals. 
Diffuse plexiform neurofibroma was seen in about 20% of the NF1 patients. The 
frequency was much higher than that in a previous report in Japan.9 The number of NF1 
patients with diffuse plexiform neurofibromas who need medical treatment has been 
increasing. 
In our study, optic pathway glioma was rarely seen in the NF1 patients (1.6%), as was 
reported previously for Japanese patients.9 The frequency was lower than in other 
countries.10 The low frequency in our study might be because imaging examination has 
not been performed for asymptomatic NF1 patients in our department. 
Regarding bone manifestations, spine deformity was most frequently seen (8.1%) in our 
study, in agreement with a previous report.9 
Based on current epidemiological data, we evaluated the grade of severity in patients 
with NF1. About 60% of the patients showed mild manifestations (stage 1 or 2), and 
about 34% of the patients had severe manifestations (stage 5). In stage 5, the most 
influential factor was diffuse plexiform neurofibromas causing functional disability. 
Although NF1 patients with mild symptoms might not visit hospitals, one third of the 
NF1 patients in our study had severe complications affecting daily life. The grade of 
severity tended to be higher in elderly patients than in younger patients. Meanwhile, 
there were a few patients with ≧1000 cutaneous neurofibromas. Some patients with 
numerous cutaneous neurofibromas had another severe complication and were classified 
into more severe grade (the stage 4 or 5). Therefore, the number of patients in stage 3 
was small.  
There is a limitation in our study because the clinical manifestation of NF1 patients is 
highly variable and some complications, e.g., pigmented macules, are not included. 
Although the DNB classifications may not be enough for the absolute evaluation of NF1 
patients severity, it represent one aspect of NF1 condition.  
In conclusion, we found that one third of the NF1 patients had severe manifestations 
with diffuse plexiform neurofibromas. Several clinical trials are currently being 
performed worldwide.19 In order to improve functional disability and impaired quality 
of life in NF1 patients, we should focus on diffuse plexiform neurofibromas and provide 
appropriate medical treatment as early as possible.  
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Figure Legends 
Figure 1) Gender and age of the 124 patients in the study population.  
Figure 2) The number of cutaneous neurofibromas. The patients were divided into 4 
groups according to the number of cutaneous neurofibromas. 
Figure 3) The number of cutaneous neurofibromas in each age. 
Figure 4) (a) Ratios of NF1 patients in each stage. (b) Ratios of manifestations in stage 
5. We defined severe plexiform neurofibromas as D4a and malignant peripheral nerve 
sheath tumor as D4b in dermatological manifestations. (c) Stages of patients according 
to age. 
 








